Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancer.

Published on Sep 7, 2016in Journal of Community Hospital Internal Medicine Perspectives
· DOI :10.3402/JCHIMP.V6.32461
Chirag C. Sheth11
Estimated H-index: 11
(San Joaquin General Hospital),
Amandeep Singh Gill2
Estimated H-index: 2
(San Joaquin General Hospital),
Sumeet Sekhon1
Estimated H-index: 1
(San Joaquin General Hospital)
Sources
Abstract
Acquired factor VIII deficiency (acquired hemophilia A) is a rare condition characterized by the acquisition of autoantibodies that affect the clotting activity of factor VIII (fVIII). The most common manifestation in affected patients is a hemorrhagic diathesis. This disorder is associated with autoimmune diseases, pregnancy, postpartum period, drugs, and malignancy. Management of this condition begins with attempts to arrest an acute bleed based on the site and severity of bleeding and inhibitor titer. The next priority is eradication of the fVIII antibodies using immunosuppressive therapies. We report the case of a 66-year-old male who presented with spontaneous right thigh hematoma with prolonged activated partial prothrombin time and normal prothrombin time. Mixing studies confirmed the presence of an inhibitor. Further investigation for the underlying etiology of acquired hemophilia A leads to diagnosis of prostate cancer. Treatment consisted of bypassing agents including activated factor VII and activated prothrombin plasma concentrate to arrest the bleeding. Steroids and cyclophosphamide were added to suppress the fVIII inhibitors . Concomitant treatment of locally advanced prostate cancer with chemotherapy confirmed the eradication of the inhibitors. To our knowledge, this is the first reported case of prostate cancer diagnosed and treated simultaneously with acquired hemophilia A resulting in favorable patient outcome.
📖 Papers frequently viewed together
20191.65Hematology
7 Authors (Naifang Ye, ..., Wenman Wu)
4 Citations
References21
Newest
#1Craig M. Kessler (GUMC: Georgetown University Medical Center)H-Index: 64
#1Craig M. Kessler (GUMC: Georgetown University Medical Center)H-Index: 31
Last. Paul Knöbl (Medical University of Vienna)H-Index: 52
view all 2 authors...
Acquired haemophilia is a potentially life-threatening bleeding disorder caused by the development of autoantibodies against coagulation factors, most commonly against factor (F) VIII (acquired haemophilia A; AHA). In around half of patients, an underlying disorder is associated with AHA; the remaining cases are idiopathic. Typically, the disorder presents with bleeding, ranging from mild to life- and limb-threatening, in patients with no personal or family bleeding history. Diagnosis involves a...
44 CitationsSource
#1Peter Collins (University Hospital of Wales)H-Index: 81
#2F BaudoH-Index: 21
Last. Angela Huth-KühneH-Index: 19
view all 9 authors...
Acquired hemophilia A (AHA) is an autoimmune disease caused by an autoantibody to factor VIII. Patients are at risk of severe and fatal hemorrhage until the inhibitor is eradicated, and guidelines recommend immunosuppression as soon as the diagnosis has been made. The optimal immunosuppressive regimen is unclear; therefore, data from 331 patients entered into the prospective EACH2 registry were analyzed. Steroids combined with cyclophosphamide resulted in more stable complete remission (70%), de...
167 CitationsSource
#1Brandi Reeves (UNC: University of North Carolina at Chapel Hill)H-Index: 10
#2Nigel S. Key (UNC: University of North Carolina at Chapel Hill)H-Index: 78
Abstract Acquired hemophilia is a rare but potentially morbid complication in patients with cancer. It may be seen in patients with hematologic neoplasms (usually lymphoproliferative disorders) or with solid tumors. Although the presence of an underlying malignancy portends a worse outcome, the literature suggests that the usual principles of treatment, including immunosuppression, apply to these patients. However, appropriate consideration should be given to the choice of agents, depending on i...
26 CitationsSource
#1Jee Young Jang (University Health System)H-Index: 1
#2Young Sig Kim (University Health System)H-Index: 1
Purpose: The results of all prostate biopsies may be positive and suggestive of adenocarcinoma in patients with prostate-specific antigen (PSA) values higher than 100 ng/ml. We considered that the prostate cancer in patients with high PSA might be advanced disease and therefore that the treatment strategy should not be changed according to pathological reports. Thus, we assessed the role of prostate biopsy when diagnosing prostate cancer in patients with extremely high PSA levels. Materials and ...
9 CitationsSource
#1M Sumner (Novo Nordisk)H-Index: 3
#2B. D. Geldziler (Novo Nordisk)H-Index: 1
Last. Stephanie Seremetis (Novo Nordisk)H-Index: 13
view all 4 authors...
Summary. Acquired haemophilia is a rare bleedingdisorder usually caused by the spontaneous forma-tion of inhibitory antibodies to coagulation FVIII.The disease occurs most commonly in the elderly,and although acquired haemophilia may be associ-ated with a variety of underlying conditions, up to50% of reported cases are idiopathic. Treatmentoptions have traditionally involved human FVIII orFIX replacement therapy (if the inhibitor titreallows), porcine FVIII or the use of activated pro-thrombin c...
154 CitationsSource
Summary. Acquired hemophilia A (AH) is an autoimmune disease that leads to potentially severe bleeding. Management relies on rapid and accurate diagnosis, control of bleeding episodes and eradication of the inhibitor by immunosuppression. There is extensive literature about the disease but only few controlled data are available. This paper reviews the current literature on treatment strategies for hemostatic therapy and inhibitor eradication. Potential future developments are discussed.
123 CitationsSource
#1David Green (NU: Northwestern University)H-Index: 79
Summary. Acquired haemophilia is a rare but life-threatening bleeding diathesis that usually is caused by autoantibodies to factor VIII (FVIII). The disorder generally affects older persons, often is linked to other autoimmune diseases or cancer, may develop in the postpartum period, and is associated with a distinct bleeding pattern. In contrast to the haemarthroses that typify congenital haemophilia, acquired haemophilia bleeds are characterized by haemorrhage into soft tissue and muscle and t...
21 CitationsSource
#1Peter Turecek (Baxter International)H-Index: 36
#2K. Varadi (Baxter International)H-Index: 4
Last. Hans Peter Schwarz (Baxter International)H-Index: 55
view all 4 authors...
Summary. FEIBA®(factor eight inhibitor bypassing activity) has a history of more than 30 years of successful use in controlling bleeding in haemophilic patients who have developed inhibitory antibodies against factor (F)VIII or FIX. Recently it was shown that FEIBA® contains the proenzymes of the prothrombin complex factors, prothrombin, FVII, FIX and FX, but only very small amounts of their activation products, with the exception of FVIIa, which is contained in FEIBA® in greater amounts. FEIBA®...
172 CitationsSource
#1S. Sallah (LSU Health Sciences Center Shreveport)H-Index: 1
Summary. Haemorrhagic manifestations in patients with acquired haemophilia can be fatal if not recognized and treated appropriately. A retrospective analysis of the efficacy of factor eight inhibitor bypassing activity (FEIBA) in patients with acquired haemophilia treated in three medical centres in the past 10 years was conducted. The median inhibitor titre at treatment was 128 Bethesda Units (BU) in patients with severe and 34 BU in patients with moderate bleeding; P = 0.001. The majority of p...
186 CitationsSource
#1Robert E. Gerstenbluth (Case Western Reserve University)H-Index: 6
#2Allen D. Seftel (Case Western Reserve University)H-Index: 51
Last. Martin I. Resnick (Case Western Reserve University)H-Index: 64
view all 5 authors...
ABSTRACTPurpose: Urologists are often referred patients who initially present with an extremely high serum prostate specific antigen (PSA) level. Despite a presumptive diagnosis of prostate cancer, many of these men undergo biopsy to obtain a tissue diagnosis before treatment with androgen ablative therapy. We examined a data base of men undergoing prostate biopsy to determine the accuracy of high PSA levels (greater than or equal to 20 ng./ml.) in predicting prostate cancer.Materials and Method...
62 CitationsSource
Cited By3
Newest
#1Akeem Lewis (SUNY Downstate Medical Center)H-Index: 1
#2Joe K. Joseph (SUNY Downstate Medical Center)H-Index: 1
Last. Carol Luhrs (SUNY Downstate Medical Center)H-Index: 14
view all 5 authors...
Acquired hemophilia A or acquired factor VIII deficiency is a rare bleeding disorder due to the presence of autoantibodies to factor VIII. It has been associated with autoimmune conditions, certain...
1 CitationsSource
#1Renata Pacholczak (Jagiellonian University Medical College)H-Index: 5
#2Stanisława Bazan-Socha (Jagiellonian University Medical College)H-Index: 9
Last. Jerzy Dropiński (Jagiellonian University Medical College)H-Index: 10
view all 7 authors...
Acquired haemophilia A (AHA) is a rare autoimmune disease caused by antibodies directed against clotting factor VIII. About half of cases are idiopathic, but AHA may also be secondary to autoimmune, dermatologic, or oncologic diseases. In approximately 10% of non-idiopathic cases, the disease occurs after or with the diagnosis of cancer as an extremely rare paraneoplastic syndrome. We describe the case of a 73-year-old male patient diagnosed with AHA and successfully treated with recombinant hum...
2 CitationsSource
#1Mariasanta Napolitano (University of Palermo)H-Index: 14
#2Sergio Siragusa (University of Palermo)H-Index: 34
Last. Craig M. Kessler (GUMC: Georgetown University Medical Center)H-Index: 31
view all 4 authors...
Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. Methods Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. Results Overall, 1...
25 CitationsSource